文献速递皮肤肿瘤

瑞典2009-2022年促纤维增生性黑色素瘤的群体登记研究:独特肿瘤特征、发病率与生存趋势

Desmoplastic melanoma in Sweden in 2009-2022: A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-01-08

基于瑞典黑色素瘤登记处2009-2022年48,945例侵袭性皮肤黑色素瘤数据,其中388例(0.8%)为促纤维增生性黑色素瘤(DM)。DM发病率0.1-0.4/10万,无显著上升趋势;原发肿瘤厚度最大(p<0.001),但调整基线预后因素后黑色素瘤特异性生存优于其他亚型(HR 0.36,95%CI 0.26-0.49)。2015-2022年诊断的DM生存较2009-2014年无显著改善(调整HR 0.99,95%CI 0.45-2.14),而其他亚型有改善(调整HR 0.74,95%CI 0.68-0.80)。

要点

  • DM占侵袭性黑色素瘤0.8%,发病率稳定在0.1-0.4/10万,无显著上升。
  • DM原发肿瘤厚度最大(p<0.001),但调整预后因素后特异性生存优于其他亚型(HR 0.36)。
  • 抗PD-1治疗引入后DM生存未显著改善(调整HR 0.99),而其他亚型有改善(调整HR 0.74)。

核心结论

  • DM发病率近年保持稳定,与其他黑色素瘤亚型上升趋势不同。
  • 尽管DM具有不良预后特征,但调整这些因素后生存优于其他亚型。
  • 抗PD-1治疗引入未显著改善DM患者生存。

研究设计与样本

  • 基于瑞典黑色素瘤登记处(SweMR)的群体登记研究。
  • 纳入2009-2022年瑞典诊断的侵袭性皮肤黑色素瘤患者。
  • 共分析48,945例侵袭性黑色素瘤,其中388例(0.8%)为DM。
  • 计算DM每10万居民发病率,比较DM与SSM、NM、LMM的生存结局。
  • 生存分析采用Kaplan-Meier法和Cox回归。

主要发现

  • 48,945例侵袭性黑色素瘤中388例(0.8%)为DM。
  • DM发病率范围为0.1-0.4例/10万,无 evident 上升,但2019-2020年男性出现一定峰值。
  • DM原发肿瘤厚度显著大于其他亚型(p<0.001)。
  • 调整基线预后因素后,DM患者黑色素瘤特异性生存改善(HR 0.36,95%CI 0.26-0.49)。
  • 2015-2022年诊断的DM较2009-2014年诊断者生存无显著改善(调整HR 0.99,95%CI 0.45-2.14),而其他亚型有改善(调整HR 0.74,95%CI 0.68-0.80)。

临床怎么用

  • DM原发肿瘤较厚,临床需注意早期识别。
  • 调整预后因素后DM生存较好,但抗PD-1治疗时代生存未显著改善,需关注治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Desmoplastic melanoma (DM) is a rare subtype, accounting for less than 5% of primary cutaneous invasive melanomas. DM often arises in chronically sun-exposed skin, in older individuals. While the incidence of cutaneous melanoma has increased globally, trends specific to DM are less documented and studies on survival outcomes for DM are inconsistent. OBJECTIVES: To study patient and tumour characteristics, incidence trends and survival outcomes of desmoplastic melanoma in comparison with other melanoma subtypes using data from the population-based Swedish Melanoma Registry (SweMR). METHODS: Clinicopathological variables were obtained from SweMR, for patients diagnosed with invasive cutaneous melanomas diagnosed in Sweden from 2009 to 2022. Incidence rates of DM per 100,000 inhabitants were calculated. DM cases were identified and survival outcomes were compared across DM, superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo maligna melanoma (LMM). Survival was analysed using Kaplan-Meier and Cox regression methods. RESULTS: Among 48,945 invasive melanomas, 388 (0.8%) were identified as DM. The incidence ranged between 0.1 and 0.4 cases per 100,000, without a evident rise, beside a certain peak in 2019-2020 in the men. DM had compared to other melanoma subtypes the thickest primary tumours (p < 0.001). When adjusting for baseline prognostic factors, DM patients had an improved melanoma-specific survival (HR 0.36, 95% CI 0.26-0.49). No significant improvement in survival was observed for DM diagnosed in 2015-2022 compared to those diagnosed in 2009-2014 (adjusted HR 0.99, 95% CI 0.45-2.14), whereas other subtypes showed an improvement (adjusted HR 0.74, 95% CI 0.68-0.80). CONCLUSIONS: In contrast to the rising incidence of other melanoma subtypes, the incidence of DM has remained more stable over recent years. Despite presenting with adverse prognostic features, survival from DM is superior when adjusting for these factors. However, the introduction of anti-PD-1 therapy has not significantly improved survival for DM patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Girmay Y, Portelli F, Mikiver R, et al. Desmoplastic melanoma in Sweden in 2009-2022: A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. J Eur Acad Dermatol Venereol. 2025. PMID: 39777919. doi:10.1111/jdv.20522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。